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DCE among Dutch health care professionals (policymakers, HTA specialists, advanced 
HTA students). In 27 choice sets, we asked respondents to elect reimbursement of one 
of two different health care interventions, which represented unlabeled, curative treat-
ments. Both treatments were incrementally compared to usual care. The results of the 
interventions were normal outputs of HTA studies with a societal perspective. Results 
were analysed using a multinomial logistic regression model. Upon completion of the 
questionnaire we discussed the exercise with policymakers. RESULTS: Severity of 
disease, costs per QALY gained, individual health gain, and the budget impact were 
the most decisive decision criteria. A program targeting more severe diseases increased 
the probability of reimbursement dramatically. Uncertainty related to the cost-effec-
tiveness ratio was also important. Respondents preferred health gains that include 
quality of life improvements over extension of life without improved quality of life. 
Savings in productivity costs were not crucial in decision making, although these are 
to be included in Dutch reimbursement dossiers for new drugs. Regarding sub groups, 
we found that policymakers attached relatively more weight to disease severity than 
others but less to uncertainty. The DCE results indicated a willingness to pay of about 
a93,000 for a QALY. This meshes nicely with the recommendations of the Dutch 
Health Care Council. CONCLUSIONS: Dutch policymakers seem to have reasonably 
well articulated preferences: six of seven attributes were signiﬁcant. Disease severity, 
budget impact, and cost-effectiveness were very important. The results are comparable 
to international studies, but reveal a larger set of important decision criteria.
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IS NICE TOO NASTY? A COMPARISON OF ANTICANCER DRUG 
COVERAGE DECISIONS IN THE UNITED STATES AND UK
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OBJECTIVES: In contrast to the US, several European countries have health technol-
ogy assessment programs (HTA) for drugs, many of which assess cost-effectiveness. 
However, restricting access to pharmaceuticals is controversial, particularly for life-
threatening diseases. Therefore the objective of this study was to assess whether eco-
nomic evaluation as part of HTA restricts access to anticancer drugs. METHODS: 
We undertook a systematic comparison of US and UK coverage decisions on anticancer 
drugs taken by the US Centers for Medicare and Medicaid (CMS), the Veterans’ Affairs 
(VA), the Regence Group (US), the National Institute for Health and Clinical 
Excellence (NICE) (UK), and the Scottish Medicines Consortium (SMC) (UK). We 
noted the timing and outcome of coverage decisions made for all anticancer drugs 
approved by the Food and Drug Administration (FDA) between 2004 and 2008. 
RESULTS: Since 2004, the FDA has approved 51 anticancer drugs, of which 39 have 
been approved by the European Medicines Agency (EMEA). On average, the FDA 
licensed these drugs 127 days earlier than EMEA. The CMS and the VA covered 
all 51 drugs from the FDA license date. The Regence group also covered all 51 
drugs, although coverage decisions that considered cost-effectiveness sometimes took 
longer. Relative to the EMEA license date, coverage decisions for anticancer drugs by 
NICE averaged 774 days (SMC: 231 days). In the US, most drugs were available 
without clinical restriction, but NICE made positive coverage decisions for just 33% 
of licensed drugs (SMC: 51%). However, US patients face substantial copayments, 
whereas drugs are free for UK cancer patients. CONCLUSIONS: The use of economic 
evaluation does lead to more restrictions on the use of anticancer drugs. However, 
the major difference between the UK and US is not whether there are restrictions on 
access to anticancer drugs, but how these are applied and who bears the decision-
making burden.
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MARKET ACCESS IN GERMANY: WHERE NEXT?
Zoellner YF1, Schaefer M2
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BACKGROUND: HTA has become the key tool to control market access for new 
technologies in Europe. This development has been mirrored in Germany through 
institutions such as DIMDI and, later, IQWiG at federal level, paralleled by similar 
tools at sickfund level. Furthermore, bilateral market access agreements appear to 
bloom. OBJECTIVES: To explore the foundation and trends of future health care 
decision-making in Germany. To formulate recommendations to manufacturers 
seeking market access for new technologies in Germany with respect to a number of 
key launch parameters. METHODS: We reviewed the development of allocative deci-
sion-making in Germany with particular attention to IQWiG (methods, international 
collaboration, decisions to date, impact). Furthermore, the role of other routes was 
examined (EVITA, rebate contracts, risk-sharing). RESULTS: IQWiG assessments 
have had a crucial impact on some products, e.g. clopidogrel and the fast-acting insulin 
analogues, and other manufacturers can learn from these decisions. While IQWiG will 
most likely cooperate with NICE and HAS on a number of issues such as evidence 
synthesis, a harmonized set of methods, leave alone decisions, cannot be expected in 
the near future. The future signiﬁcance of other access routes still needs to be deter-
mined. CONCLUSIONS: Manufacturers must be prepared for IQWiG assessments 
to be used for pricing purposes. Evidence must stem from randomized controlled 
trials wherever possible. Cost-effectiveness analysis will remain a second step of the 
appraisal, to which a new technology will only be admitted after having overcome a 
stand-alone effectiveness assessment. Neither QALYs nor a cost-per-QALY threshold 
will be used for decision-making. Germany will continue to grant high rewards to 
innovation, but careful thought must be given by manufacturers on how to present 
the added value of such innovations—be it via the IQWiG, a potential EVITA, or a 
direct contracting route.
PODIUM SESSION II: MODELING METHODS I
MO1
COHORT MODELLING—IS THE APPROACH TOO OLD FOR THE 
ELDERLY?
Ethgen O1, Demarteau N2, Standaert BA2
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OBJECTIVE: Elderly (65y) are steadily growing, but this population segment is also 
the one in whom mortality, morbidity and health care costs increase sharply with age 
as a result of co-morbidity and greater frailty. This project intends to document the 
implications of using different modelling approaches on the beneﬁt evaluation of a 
public health intervention in elderly. METHODS: We designed a mathematical model 
to simulate the effect of a hypothetical public health intervention aiming at reducing 
mortality in the 65 y. The simulation is run on an elderly population of 1,000,000 
individuals (age weighted average of 75.66 y). The impact of the intervention is com-
pared between a cohort model (i.e., average parameters applied to the 75.66 year- old 
elderly cohort) and a population model (i.e., age-speciﬁc parameters applied to the 
entire elderly population). Life-expectancy gains (LEG) from both approaches were 
computed between intervention and no-intervention. Various scenarios were com-
pared through a range of different mathematical speciﬁcations of age-speciﬁc inter-
vention coverage and mortality reduction. RESULTS: In the cohort approach, life 
expectancies were respectively 11.38 and 11.48 years between no-intervention and 
intervention, i.e. a LEG of 0.10 y for the 75.66 y-old elderly cohort. In the population 
approach, age-speciﬁc life expectancies averaged 11.51 and 12.19 y between no-
 intervention and intervention, respectively. This translated into a weighted average 
LEG of 0.52 y, i.e. a gain 5-times higher than in the cohort approach. This result was 
conﬁrmed in various scenarios. CONCLUSION: Population modelling, whilst being 
potentially more data-hungry and mathematically demanding, allows for more com-
prehensive consideration of age-speciﬁc parameters in the decision-making process. 
This approach has the potential to better capture the whole beneﬁt of a population-
wide intervention which is particularly insightful in the elderly for whom mortality, 
disability and costs of health care are even more age-sensitive.
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IMPROVING COST-EFFECTIVENESS ANALYSES OF BEHAVIOURAL 
INTERVENTIONS BY USING COGNITIVE INTERMEDIATE OUTCOMES:  
A PILOT STUDY
Prenger R1, Pieterse ME1, Braakman-Jansen LM1, van der Palen J2, Seydel ER1
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OBJECTIVES: Cost-effectiveness analyses of behavioural health interventions typi-
cally use a dichotomous outcome criterion (success or failure). However, achieving 
behavioural change is a complex process in which several steps towards behavioural 
change are taken. Delayed behavioural effects may occur after an intervention or 
follow-up period ends, which can lead to underestimation of these interventions. As 
extending the follow-up period is often impeded by practical and ﬁnancial limitations, 
intermediate outcomes of behavioural change can be modelled into the cost-
 effectiveness ratio. The aim of this study is to model intermediate cognitive outcomes 
into a cost-effectiveness model of a behavioural intervention, comparing an intensive 
smoking cessation program (SST) with a less intensive smoking cessation program 
(LMIS) for COPD outpatients. METHODS: The cost-effectiveness analysis of an 
existing dataset was replicated by modelling the stages of change of the Transtheoreti-
cal Model of behavioural change. This stage-oriented model describes the readiness 
to change in qualitatively different, discrete stages; the ‘stages of change’. Costs were 
adjusted for the different stages of change participants were in. Probabilities to predict 
future behavioural change were obtained from the dataset and literature. Finally, a 
sensitivity analysis was performed. RESULTS: In the ﬁrst 12 months, the SST domi-
nated the LMIS in approximately 50% of the cases. By modelling the intermediate 
cognitive determinants to a future second year of follow-up, the SST dominated the 
LMIS in approximately 75% of all cases. CONCLUSIONS: This study showed that 
modelling of future behavioural change in cost-effectiveness analysis of a behavioural 
intervention led to a more favourable result. Further research should focus on collect-
ing longitudinal data of the cognitive determinants for different populations and 
outcome measures to be able to make a valid prediction of future behavioural change. 
Ultimately, this could have important consequences for health policy development in 
general and the adoption of behavioural interventions in particular.
MO3
R THERE ANY DIFFERENCES BETWEEN EXCEL AND R? COMPARISON 
OF ICER ESTIMATES AND CEACS OBTAINED FROM A MODEL 
IMPLEMENTED IN MICROSOFT EXCEL AND R
Bischof M, Lim ME, Ferrusi IL, Burke N, Blackhouse G, Goeree R, Tarride JE
McMaster University, Hamilton, ON, Canada
OBJECTIVES: Comparison of the results of a decision analytic model developed in 
Microsoft Ofﬁce Excel® 2007 versus an implementation of the same model in R 
version 2.8.1 (www.R-project.org). The aim was to identify any difference in the per-
formance and validity between models implemented with the two software packages 
in terms of incremental cost-effectiveness ratio (ICER) estimates and probabilistic 
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sensitivity analysis (PSA) results. METHODS: Decision analytic models were devel-
oped in Excel and R to assess the cost-effectiveness of a hypothetical therapy for a 
hypothetical, chronic disease. The models consisted of a decision tree (22 branches) 
for the ﬁrst year of therapy and of a Markov model to capture long-term costs and 
effects. Both models comprised 24 decision nodes and 6 Markov models. All costs, 
effectiveness and utility parameters were hypothetical. Probabilistic sensitivity analysis 
was used to assess decision uncertainty by performing 10 000 Monte Carlo simula-
tions. RESULTS: The incremental cost-effectiveness ratio (ICER) of the new therapy 
was $75,962.164371494/QALY when calculated with R and $75,962.164371494/
QALY when calculated with Excel. At a threshold value of $50,000 per QALY, the 
probability that the hypothetical treatment is cost-effective was 14.5% when calcu-
lated with Excel and 13.6% when using R. At the higher thresholds of $100,000 and 
$150 000 per QALY, the probabiliy estimates increased to 80.4% (Excel) and 80.6% 
(R) and 98.0% (Excel) and 98.1% (R), respectively. CONCLUSIONS: Excel and R 
allow building and analyzing complex decision models. As we showed, both model 
implementations yield the same results when calculating an ICER, up to 14 digits. The 
difference in PSA results might have been due to their probabilistic nature (here: 
10,000 iterations). Both packages have been used for medical decision making. Choos-
ing one package over the other does not need to be performance-based and can be 
left to personal preference.
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BAYESIAN GENERALIZED LINEAR MODELLING OF THE RELATIONSHIP 
BETWEEN HEALTH ASSESSMENT QUESTIONNAIRE-DISABILITY INDEX 
AND HEALTH UTILITIES INDEX MARK III IN EARLY AND LATE 
RHEUMATOID ARTHRITIS: DATA FROM THE PREMIER AND  
ARMADA TRIALS
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OBJECTIVES: Many cost-effectiveness analyses in rheumatoid arthritis (RA) rely on 
statistical models relating Health Assessment Questionnaire Disability Index (HAQ) 
scores to health utilities. Linear models can produce out-of-bound estimates of Health 
Utilities Index Mark 3 (HUI3) scores. We estimated bounded, nonlinear relationships 
between HAQ and HUI3 based on patient-level data. METHODS: Bayesian general-
ized linear models (GLMs) were developed to predict baseline HUI3 conditional on 
baseline HAQ using patient-level data from the PREMIER (2-year controlled study in 
early RA) and ARMADA (24-week controlled study in longstanding RA) trials. HUI3 
was rescaled to the interval [0,1] and modeled using a beta distribution and logistic 
link function. Normal-linear models were also estimated. Alternative speciﬁcations 
included age, sex, and HAQ-squared as additional predictors. Model parameters were 
estimated using WinBUGS 1.4.3. Models were compared using the deviance informa-
tion criterion (DIC); lesser values imply better ﬁt. Predicted values from beta-logistic 
models were linearly retransformed to the original HUI3 scale. RESULTS: Results 
were similar in early and late RA. Based on DIC, the beta-logistic models were more 
likely to generate the observed data than were the normal-linear models (PREMIER: 
–673.0 vs. –614.4; ARMADA: –226.1 vs. –215.8). Qualitatively, predictions from the 
beta-logistic models differed modestly from the normal-linear model. At low disability 
(HAQ  0.0), predicted HUI3 utilities were 0.75 vs. 0.81 (PREMIER) and 0.74 vs. 
0.79 (ARMADA) for the beta-logistic and normal-linear models, respectively. At high 
disability (HAQ  3.0), predicted HUI3 utilities were –0.03 vs. –0.05 (PREMIER) and 
0.01 vs. 0.01 (ARMADA). Age, sex, and HAQ-squared did not improve DIC. CON-
CLUSION: There is a strong negative relationship between HAQ and HUI3. Although 
the overall relationship is nonlinear, the linear approximation seems close across 
the relevant range of HAQ scores (0–3). Considering the complexity of the GLM 
approach, normal-linear regression may be adequate for cost-effectiveness analyses.
PODIUM SESSION II: PATIENT PREFERENCE STUDIES
PP1
A SYSTEMATIC REVIEW OF THE ANALYTIC HIERARCHY PROCESS IN 
HEALTH CARE DECISION MAKING
Hummel JM, IJzerman MJ
University of Twente, Enschede, The Netherlands
OBJECTIVES: The analytic hierarchy process (AHP), a technique for multi-criteria 
decision analysis, is increasingly being used to support health care decision making. 
These decisions mainly relate to the application and coverage of health care technolo-
gies, and its use as a patient-reported outcome measure. The objective of this study is 
to review the use of this upcoming technique in health care; the Analytic Hierarchy 
Process. METHODS: We conducted a systematic review of the relevant medical, 
health-economical, psycho-sociological, managerial, and applied mathematical litera-
ture. We used the keywords “Analytic Hierarchy Process” AND (“patient” OR 
“patients” OR “health” OR “health care” OR “medical” OR “clinical” OR “hospi-
tal”) to search in the general topic of the articles within in the databases PubMed and 
Web of Science. RESULTS: We found 57 distinctive AHP applications in health care. 
Of the retrieved applications, 13 % focus on shared decision-making between patient 
and clinician, 25 % on the development of clinical practice guidelines, 5 % on the 
development of medical devices and pharmaceuticals, 44 % on management decisions 
in health care organizations, and 13 % on the development of national health care 
policy. CONCLUSIONS: From the review it is concluded that the AHP is frequently 
used and provides valuable support in complex health care decisions. The AHP is 
suitable to apply in case of complex health care decision problems, a need to improve 
decision making instead of explain decision outcomes, a need to share information 
among experts or between clinicians and patients, and in case of a limited availability 
of informed respondents. We also foresee the use of the AHP in conducting compre-
hensive Health Technology Assessments involving multiple stakeholders. Only for 
these speciﬁc types of decision problems, we recommend the use of the AHP.
PP2
PATIENT PREFERENCES FOR BENEFIT-RISK TRADEOFFS AMONG 
POST-TRANSPLANT OUTCOMES IN END-STAGE RENAL DISEASE
Johnson FR1, Hauber AB1, Mohamed AF1, Gonzalez JM2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI HEalth Solutions, Research 
Triangle Park, NC, USA
The Food and Drug Administration Amendments Act of 2007 requires FDA to develop 
and implement plans for evaluating beneﬁts and risks of new pharmaceuticals. Quan-
titative approaches to comparing therapeutic beneﬁts and risks thus are increasingly 
of interest to regulators and industry decision makers. OBJECTIVES: To quantify 
beneﬁt-risk tradeoff preferences for post-transplant outcomes among chronic kidney-
disease patients at risk for kidney transplant and estimate maximum acceptable 
adverse-event risks for speciﬁed efﬁcacy improvements. METHODS: US residents aged 
18 years or older with a self-reported diagnosis of chronic kidney failure or end-stage 
kidney disease completed a web-enabled survey instrument that presented a series of 
trade-off questions, each including a pair of hypothetical post-transplant outcome 
proﬁles. Each proﬁle was deﬁned by ﬁve efﬁcacy attributes and three life-threatening 
adverse-event attributes. Each subject answered 9 trade-off questions based on a pre-
determined experimental design with known statistical properties. RESULTS: A total 
of 233 subjects completed the survey. Subjects judged life expectancy to be more than 
three times more important than the next most important outcome. There were sig-
niﬁcant differences in preferences between older and younger subjects. Subjects over 
age 54 judged risks of impaired renal function, graft loss, acute rejection, infection, 
and malignancy as similarly important and progressive multifocal leukoencephalopa-
thy (PML) risk as much less important. Subjects under age 54 judged risks of acute 
rejection, malignancy, and PML as unimportant. Maximum acceptable risk of serious 
infection for a one-year increase in expected survival was 8.5% (5.1%–17.7%) and 
1.6% (0.9%–3.1%) for older and younger subjects, respectively. CONCLUSIONS: 
The beneﬁt-risk tradeoff data obtained in this study support valid estimates of 
maximum acceptable adverse-event risks in different patient populations. These esti-
mates of risk tolerance provide a useful quantitative approach to identifying treat-
ments where acceptable risk levels exceed actual risk levels by signiﬁcant margins.
PP3
WHAT DIMENSIONS ARE IMPORTANT TO PATIENTS IN THEIR 
EXPERIENCE OF CONTINUITY OF CARE? A STUDY OF PATIENTS’ 
PREFERENCES USING A DISCRETE CHOICE EXPERIMENT
Kjaer T1, Bech M1, Draborg E1, Mollerup M2
1University of Southern Denmark, Odense, Denmark, 2Odense University Hospital, Odense, 
Denmark
OBJECTIVES: Many patients experience complex disease courses raising concerns 
about fragmentation of care and continuity. The objective of the present study was 
to explore which dimensions that are important to patients in their experience of 
continuity of care. Patients’ preferences were elicited using a discrete choice experiment 
(DCE). METHODS: 1800 patients were invited to participate in a postal survey 
including three patient groups; diabetics, heart patients and cancer patients. Random 
samples of each of the deﬁned patient groups were recruited through Odense Univer-
sity Hospital given at least one admission during the last two years. The DCE con-
tained ﬁve attributes; 1) Involvement of GP in the patient’s course of disease; 2) 
Arrangement of a contact person at the hospital; 3) Involvement of the patient in the 
decisions; 4) Yearly consultation at hospital; and 5) Distance to hospital. RESULTS: 
Data was collected in the period April-June 2009 and resulted in an overall response 
rate of 67%. Primary analyses of DCE data are promising. All respondents value 
patient involvement in the treatment decision highly whereas the involvement of GPs 
matters less—in particular to diabetic patients and cancer patients. We observe some 
differences in preferences among diabetes compared to the two other patient groups. 
Notably heart and cancer patients ﬁnd the offer of yearly consultation unimportant 
and ﬁnd the arrangement of a contact person objectionable. These two differences 
likely indicate patients’ (dis)satisfaction with the health care system and the current 
organisation of treatment and as such may reﬂect some lack of continuity of care. 
CONCLUSIONS: Worldwide there has been a policy focus on enhancing patients’ 
satisfaction and enhancing continuity of care among patients. The present study con-
tributes to this work by examining what dimensions that are deemed important by 
patients in their experience with the health care system during their disease courses.
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LIVES WORTH LIVING: OLDER SMOKERS’ STATED PREFERENCES  
FOR LONGEVITY
Johnson FR1, Smith VK2, Smith GA3, Gonzalez JM4
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USA, 3University of Michigan, Ann Arbor, MI, USA, 4RTI Health Solutions, Research Triangle 
Park, NC, USA
The US Food and Drug Administration recently was granted new authority to regulate 
tobacco-related risks. While the morbidity and mortality beneﬁts of smoking cessation 
